Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Proshares Trust (ZBIO) Operating Income (2023 - 2025)

Historic Operating Income for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to -$52.6 million.

  • Zenas BioPharma's Operating Income fell 2829.4% to -$52.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$200.7 million, marking a year-over-year decrease of 5085.05%. This contributed to the annual value of -$163.9 million for FY2024, which is 34118.77% down from last year.
  • Latest data reveals that Zenas BioPharma reported Operating Income of -$52.6 million as of Q3 2025, which was down 2829.4% from -$55.2 million recorded in Q2 2025.
  • Zenas BioPharma's Operating Income's 5-year high stood at $35.6 million during Q3 2023, with a 5-year trough of -$55.6 million in Q4 2024.
  • Over the past 3 years, Zenas BioPharma's median Operating Income value was -$39.7 million (recorded in 2024), while the average stood at -$33.1 million.
  • Per our database at Business Quant, Zenas BioPharma's Operating Income tumbled by 21504.6% in 2024 and then crashed by 2829.4% in 2025.
  • Over the past 3 years, Zenas BioPharma's Operating Income (Quarter) stood at -$24.8 million in 2023, then plummeted by 124.48% to -$55.6 million in 2024, then grew by 5.47% to -$52.6 million in 2025.
  • Its Operating Income was -$52.6 million in Q3 2025, compared to -$55.2 million in Q2 2025 and -$37.3 million in Q1 2025.